Research suggests the use of additional treatment options, such as the mineralocorticoid receptor antagonist eplerenone, might prevent or delay overt diabetic nephropathy.
In a European study, approximately one-third of hospitalizations involving patients with recurrent hyperkalemia directly related to serum potassium elevation.
Secondary results from the DAPA-HF trial suggest the sodium-glucose cotransporter 2 inhibitor may enable use of mineralocorticoid receptor antagonists in some patients with heart failure.
Patients with a hyperkalemia-related hospitalization have significantly higher readmission rates over 12 months than patients with other reasons for hospitalization.
In a Swiss study of patients who made emergency department visits, significant proportions of those with acute kidney injury had hyperkalemia or hypokalemia.
Investigators observed a complex interaction between serum and fecal potassium, calcium, and magnesium during patiromer treatment in patients on hemodialysis.
Patients hospitalized with COVID-19 who have preexisting kidney conditions are more susceptible to renal complications, a new systematic review and meta-analysis suggest.
